FDA Emergency Use Authorizations for combatting COVID-19
| Intervention | Company | EUA date | Comments |
|---|---|---|---|
| Chloroquine, hydroxychloroquine | – | 28 March | EUA revoked 15 June |
| Veklury (remdesivir) | Gilead Sciences | 30 April | Antiviral, full approval 22 October |
| COVID-19 convalescent plasma | – | 23 August | Passive immunotherapy |
| Bamlanivimab | Eli Lilly | 9 November | Passive immunotherapy |
| Olumiant (baricitinib) with remdesivir | Eli Lilly and Gilead Sciences | 19 November | Immune storm reduction, antiviral |
| Casirivimab and imdevimab | Regeneron | 20 November | Passive immunotherapy |
| COVID-19 vaccine | Pfizer and BioNTech | 11 December | mRNA vaccine |
| COVID-19 vaccine | Moderna Therapeutics | 17 December | mRNA vaccine |
EUA, emergency use authorization. Source: US FDA, https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#covidtherapeutics